PAP
NKTR icon

Persistent Asset Partners’s Nektar Therapeutics NKTR Stock Holding History

Persistent Asset Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,560
Closed -$8.67K – 277
2025
Q2 		$8.67K Buy
1,560
+1,456
+1,400% +$16.3K 0.01% 171
2025
Q1 		$36.7K Hold
104
– – 0.03% 138
2024
Q4 		$73.4K Buy
+104
New +$1.83K 0.06% 108

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Persistent Asset Partners's NKTR Position: Q2 2026 in Review

Persistent Asset Partners increased its Nektar Therapeutics (NKTR) stake by 29% in Q2 2026, buying an estimated $122K and bringing the position to 7,481 shares worth $522K. The position accounts for 0.16% of the portfolio, ranked #107.

Persistent Asset Partners first reported a position in NKTR in Q4 2024 and has held it in 4 quarters since. The position peaked at $983K in Q3 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Persistent Asset Partners held 7,481 shares of Nektar Therapeutics worth $522K as of Q2 2026.
  • Persistent Asset Partners bought 1,661 Nektar Therapeutics shares in Q2 2026, an estimated $122K.
  • Nektar Therapeutics made up 0.16% of Persistent Asset Partners's portfolio in Q2 2026, its #107 holding.
  • Persistent Asset Partners first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Persistent Asset Partners's Nektar Therapeutics position peaked at $983K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.